日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Breakthrough Therapy Designation Criteria Identify Drugs that Improve Clinical Outcomes for Patients: A Case for More Streamlined Coverage of Promising Therapies

突破性疗法认定标准旨在识别能够改善患者临床疗效的药物:有必要简化对有前景疗法的医保覆盖范围

Collins, Grace; Stewart, Mark; McKelvey, Brittany; Stires, Hillary; Allen, Jeff

Sponsor Perspectives on the Impact of the COVID-19 Pandemic on Interventional Cancer Clinical Trial Protocols and Data Quality

申办方对 COVID-19 疫情对介入性癌症临床试验方案和数据质量影响的看法

Unger, Joseph M; Stires, Hillary; Levit, Laura A; Stewart, Mark; McKelvey, Brittany Avin; Canin, Beverly; Dressler, Emily; Flaherty, Keith; Fredette, Peter; Jones, Lee; McCann, Peggy; Miller, Therica; Onitilo, Adedayo A; Palmieri, Fran; Patel, Timil; Paul, Rocio; Smith, Gary L; Bruinooge, Suanna S; Garrett-Mayer, Elizabeth; Lei, Xiudong Jennifer; Alva, Ajjai; Schenkel, Caroline

Riluzole Suppresses Growth and Enhances Response to Endocrine Therapy in ER+ Breast Cancer

利鲁唑可抑制ER+乳腺癌的生长并增强其对内分泌治疗的反应

Ayodeji O Olukoya ,Hillary Stires ,Shaymaa Bahnassy ,Sonali Persaud ,Yanira Guerra ,Suman Ranjit ,Shihong Ma ,M Idalia Cruz ,Carlos Benitez ,Aaron M Rozeboom ,Hannah Ceuleers ,Deborah L Berry ,Britta M Jacobsen ,Ganesh V Raj ,Rebecca B Riggins

ROS is a master regulator of in vitro matriptase activation

ROS 是体外基质裂解酶活化的主要调节剂

Darius O Gaymon, Robert Barndt, Hillary Stires, Rebecca B Riggins, Michael D Johnson

Improving the odds together: a framework for breast cancer research scientists to include patient advocates in their research

携手提高成功率:乳腺癌研究科学家将患者权益倡导者纳入研究的框架

Stires, Hillary; Bado, Igor; Brown, Thelma; Carlson, Martha; Chan, Isaac S; Echeverria, Gloria V; Ewald, Andrew J; Lim, Bora; Lloyd, Carla; Maues, Julia; Oesterreich, Steffi; Riter, Robert N; Shanahan, Kelly; Welm, Alana L; Newby, Josh

Homologous Recombination Deficiency: Concepts, Definitions, and Assays

同源重组缺陷:概念、定义和检测

Stewart, Mark D; Merino Vega, Diana; Arend, Rebecca C; Baden, Jonathan F; Barbash, Olena; Beaubier, Nike; Collins, Grace; French, Tim; Ghahramani, Negar; Hinson, Patsy; Jelinic, Petar; Marton, Matthew J; McGregor, Kimberly; Parsons, Jerod; Ramamurthy, Lakshman; Sausen, Mark; Sokol, Ethan S; Stenzinger, Albrecht; Stires, Hillary; Timms, Kirsten M; Turco, Diana; Wang, Iris; Williams, J Andrew; Wong-Ho, Elaine; Allen, Jeff

OR16-5 Riluzole suppresses growth and enhances response to endocrine therapy in ER+ breast cancer

OR16-5 利鲁唑可抑制ER+乳腺癌的生长并增强其对内分泌治疗的反应

Goncalves, Rodrigo; DeSchryver, Katherine; Ma, Cynthia; Tao, Yu; Hoog, Jeremy; Cheang, Maggie; Crouch, Erika; Dahiya, Neha; Sanati, Souzan; Barnes, Michael; Sarian, Luis Otávio Zanatta; Olson, John; Allred, Donald Craig; Ellis, Matthew J; Prystupa, Yuliya; Bahnassy, Shaymaa; Benitez, Carlos; Cruz, M Idalia; Guerra, Yanira; Ma, Shihong; Persaud, Sonali; Raj, Ganesh; Riggins, Rebecca; Stires, Hillary; Olukoya, Ayodeji

Symptom rates and profile clustering in tuberous sclerosis complex-associated neuropsychiatric disorders (TAND)

结节性硬化症相关神经精神疾病(TAND)的症状发生率和特征聚类

Alperin, Samuel; Krueger, Darcy A; Franz, David N; Agricola, Karen D; Stires, Gabrielle; Horn, Paul S; Capal, Jamie K

SAT-119 Targeting Glutamate Metabolism and Signaling in ER+, Endocrine Therapy-Resistant Breast Cancer

SAT-119靶向ER+、内分泌治疗耐药乳腺癌中的谷氨酸代谢和信号传导

Jacobsson, B; Carlström, A; Collins, V P; Grimelius, L; Araki, Takako; Kameda, Hiraku; Yamamoto, Masaaki; Tateno, Toru; Iwasaki, Yasumasa; Yu, Run; Radulescu, Angela; Burmeister, Lynn; Fukuoka, Hidenori; Olukoya, Ayodeji O; Stires, Hillary; Guerra, Yanira; Persaud, Sonali; Ma, Shihong; Raj, Ganesh V; Riggins, Rebecca B

Integrated molecular analysis of Tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGluR signaling as therapeutic vulnerabilities

对耐他莫昔芬浸润性小叶乳腺癌细胞的整合分子分析表明,MAPK 和 GRM/mGluR 信号通路是治疗靶点。

Stires, Hillary; Heckler, Mary M; Fu, Xiaoyong; Li, Zhao; Grasso, Catherine S; Quist, Michael J; Lewis, Joseph A; Klimach, Uwe; Zwart, Alan; Mahajan, Akanksha; Győrffy, Balázs; Cavalli, Luciane R; Riggins, Rebecca B